“Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation” (2018) Farmeconomia. Health Economics and Therapeutic Pathways, 19(1). doi:10.7175/fe.v19i1.1346.